The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Andreeva Yu.S.

Krasnov Research Institute of Eye Diseases

Alkharki L.

Krasnov Research Institute of Eye Diseases

Shelankova A.V.

Krasnov Research Institute of Eye Diseases

Budzinskaya M.V.

Krasnov Research Institute of Eye Diseases

Topical application of hypotensive drugs for the prevention of intraocular pressure elevation after intravitreal injections of anti-VEGF drugs

Authors:

Andreeva Yu.S., Alkharki L., Shelankova A.V., Budzinskaya M.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2024;140(2‑2): 73‑79

DOI: 10.17116/oftalma202414002273

Read: 1759 times

Download PDF (RU)
Contact the author
Table of contents

TOPICAL APPLICATION OF HYPOTENSIVE DRUGS FOR THE PREVENTION OF INTRAOCULAR PRESSURE ELEVATION AFTER INTRAVITREAL INJECTIONS OF ANTI-VEGF DRUGS
TOPICAL APPLICATION OF HYPOTENSIVE DRUGS FOR THE PREVENTION OF INTRAOCULAR PRESSURE ELEVATION AFTER INTRAVITREAL INJECTIONS OF ANTI-VEGF DRUGS

To cite this article:

Andreeva YuS, Alkharki L, Shelankova AV, Budzinskaya MV. Topical application of hypotensive drugs for the prevention of intraocular pressure elevation after intravitreal injections of anti-VEGF drugs. Russian Annals of Ophthalmology. 2024;140(2‑2):73‑79. (In Russ.)
https://doi.org/10.17116/oftalma202414002273

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Long-term outcomes of phakic intraocular lens implantation in high myopia. Russian Annals of Ophthalmology. 2025;(1):28-31
Proton pump inhi­bitors: posi­tive and nega­tive properties. On the 45th anni­versary of their discovery. Russian Journal of Preventive Medi­cine. 2024;(11):135-140
Study of opinions of medi­cal students on medi­cal prevention issues. Russian Journal of Preventive Medi­cine. 2024;(12):69-74
Asse­ssment of risk of deve­loping fractures and sarcopenia and quality of life of patients with chro­nic kidney disease at the outpatient stage. Russian Journal of Preventive Medi­cine. 2024;(12):88-91
Gastric cancer: inci­dence, risk factors, screening. Russian Journal of Preventive Medi­cine. 2024;(12):135-139
The rela­tionship of diet and nutrition with the frequency of migraine atta­cks. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):30-35
Prevention of periodontal inflammation in microgravity mode­ling. Stomatology. 2024;(6-2):23-28
Effe­ctiveness of risk-guided cardiac mana­gement in patients with HER2-positive breast cancer and cancer therapy-related cardiac dysfunction. Russian Cardiology Bulletin. 2024;(4-2):144-153
Obstructive sleep apnea syndrome as a predictor of atrial fibrillation. Russian Journal of Preventive Medi­cine. 2025;(1):109-114
Vita­min D role in oral cavity diseases. Stomatology. 2025;(1):81-86
Abstract:

The management protocol for patients with neovascular age-related macular degeneration (nAMD) involves multiple intravitreal injections (IVI) of anti-VEGF drugs. The ability to reduce the peak intraocular pressure (IOP) rise is greatly important in clinical practice.

PURPOSE

This study evaluates the effect of topical hypotensive drugs on the short-term IOP rise after IVI of anti-VEGF drugs in patients with nAMD.

MATERIAL AND METHODS

The prospective study included 80 patients with newly diagnosed nAMD. Before the start of treatment, the patients were divided into 4 groups of 20 people each: 1st — controls, who received no prophylactic drugs, in the 2nd, 3rd and 4th groups local instillations of one drop of hypotensive drugs brinzolamide 1%, brinzolamide-timolol, brimonidine-timolol were performed in the conjunctival sac twice: 1 day before the injection (at 20:00) and on the day of the injection 2 hours before the manipulation (at 08:00), respectively. IOP was measured in each patient using ICare Pro non-contact tonometer before injection, as well as 1 min, 30 and 60 min after injection.

RESULTS

Prophylactic use of hypotensive drugs was associated with a significant decrease in IOP immediately after IVI compared to the same parameter in the 1st group (p<0.001), the maximum decrease in IOP values was observed when using a fixed combination of brimonidine-timolol by 12.1 mm Hg compared to the controls (p<0.001), the combination of brinzolamide-timolol reduced IOP by 8.5 mm Hg (p<0.001), brinzolamide 1% led to the smallest decrease in IOP — by 5.1 mm Hg (p<0.001).

CONCLUSION

Study patients that received instillations of brimonidine-timolol combination of one drop into the conjunctival sac 1 day before the injection and on the day of the injection showed the maximum decrease in IOP compared to patients of the other groups.

Keywords:

anti-VEGF drugs
intravitreal injection
intraocular pressure
prevention

Authors:

Andreeva Yu.S.

Krasnov Research Institute of Eye Diseases

Alkharki L.

Krasnov Research Institute of Eye Diseases

Shelankova A.V.

Krasnov Research Institute of Eye Diseases

Budzinskaya M.V.

Krasnov Research Institute of Eye Diseases

Received:

05.02.2023

Accepted:

11.02.2024

Close metadata

References:

  1. Bandello F, De Benedetto U, Knutsson K. Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol. 2011;5:1303-1308. https://doi.org/10.2147/OPTH.S17423
  2. Rosenfeld P, Brown D, Heier J. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1143. https://doi.org/10.1056/NEJMoa054481
  3. Budzinskaia MV, Pliukhova AA, Toropygin SG. Modern view on the treatment of wet-AMD patients. Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(5):107-115. (In Russ.). https://doi.org/10.17116/oftalma2019135051107
  4. Fursova AZh, Derbeneva AS, Vasilyeva MA, Tarasov MS, Chubar NV, Nikulich IF. Different types localisation of retinal fluid as prognostic biomarkers in the choice of anti-VEGF therapy for age-related macular degeneration. Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2020;136(6): 227-234. (In Russ.). https://doi.org/10.17116/oftalma2020136061227
  5. Bakri S, Pulido J, McCannel C. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond). 2009;23:181-185.  https://doi.org/10.1038/sj.eye.6702938
  6. Fursova AZh, Gamza YuA, Derbeneva AS, Vasilyeva MS. Anti-angiogenesis therapy of diabetic macular edema in patients with primary open-angle glaucoma. Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2020; 136(6):185-194. (In Russ.). https://doi.org/10.17116/oftalma2020136061185
  7. Murray C, Wood D, Allgar V, Walters G, Gale R. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients. Eye (London, England). 2014;28(10):1218-1222. https://doi.org/10.1038/eye.2014.180
  8. Bauer SM, Voronkova EB, Kotliar KE. On elevation of intraocular pressure after intravitreal injections. Russian Ophthalmological Journal. 2021;14(4):126-129. (In Russ.). https://doi.org/10.21516/2072-0076-2021-14-4-126-129
  9. Loskutov IA, Melnikova LP, Kalugina ON. Intraocular pressure after intravitreal injections of VEGF inhibitors. National Journal glaucoma. 2017;16(1): 38-45. (In Russ.).
  10. Hoguet A, Chen P, Junk A. The effect of anti- vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of ophthalmology. Ophthalmology. 2019; 126:611-622.  https://doi.org/10.1016/j.ophtha.2018.11.019
  11. Bressler S, Almukhtar T, Bhorade A, et al. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol. 2015;133:589-597.  https://doi.org/10.1001/jamaophthalmol.2015.186
  12. Eadie B, Etminan M, Carleton B, et al. Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery. JAMA Ophthalmol. 2017;135:363-368.  https://doi.org/10.1001/jamaophthalmol.2017.0059
  13. Bracha P, Moore N, Ciulla T, Cantor L. The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A Review. Survey of Ophthalmology. 2018;63(3):281-295.  https://doi.org/10.1016/j.survophthal.2017.08.008
  14. Fursova AZh, Gamza YA, Derbeneva AS, Vasil’eva MA. Impact of antiangiogenic therapy on the hemodynamics of the optic nerve and macula in patients with diabetic macular edema and glaucoma. Bulletin of Pirogov National Medical & Surgical Center. 2021;16(1):93-98. (In Russ.). https://doi.org/10.25881/BPNMSC.2021.33.54.016
  15. Soheilian M, Karimi S, Montahae T, et al. Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study. Graefes Arch Clin Exp Ophthalmol. 2017;255(9):1705-1712. https://doi.org/10.1007/s00417-017-3702-114
  16. Rud’ko A, Budzinskaya M, Andreeva I, Karpilova M, Smirnova T. Effect of intravitreal injections of ranibizumab and aflibercept on the retinal nerve fiber layer in patients with concomitant neovascular age-related macular degeneration and glaucoma. Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(5-2):177-183. (In Russ.). https://doi.org/10.17116/oftalma2019135052177
  17. Barash A, Chui T, Garcia P, Rosen R. Acute macular and peripapillary angiographic changes with intravitreal injections. Retina. 2020;40(4):648-656.  https://doi.org/10.1097/IAE.0000000000002433
  18. El Chehab H, Le Corre A, Agard E, et al. Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection. Eur J Ophthalmol. 2013;23(3):277-283.  https://doi.org/10.5301/ejo.500015918
  19. Felfeli T, Hostovsky A, Trussart R. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial. Br J Ophthalmol. 2019;103:1388-1394. https://doi.org/10.1136/bjophthalmol-2018-312603
  20. Katayama B, Bonini-Filho M, Messias A, et al. Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: a randomized clinical trial. J Glaucoma. 2014;23:461-463.  https://doi.org/10.1097/ijg.0b013e3182948476
  21. Theoulakis P, Lepidas J, Petropoulos I, et al. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd. 2010; 227:280-284.  https://doi.org/10.1055/s-0029-1245201
  22. Dettoraki M, Rapti E, Fragkos D, et al. Prophylactic effect of brinzolamide — brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections. Int Ophthalmol. 2021;41:3191-3198. https://doi.org/10.1007/s10792-021-01885-z
  23. Shoeibi N, Ghosi Z, Jafari H, et al. Effect of antiglaucoma agents on short-term intraocular pressure fluctuations after intravitreal bevacizumab injections. Int Ophthalmol. 2021;41:1081-1090. https://doi.org/10.1007/s10792-020-01667-z
  24. Frenkel M, Haji S, Frenkel R. Effect of prophylactic intraocular pressure — lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol. 2010;128(12):1523-1527. https://doi.org/10.1001/archophthalmol.2010.297
  25. Carnota-Mendez P, Mendez-Vazquez C, Otero-Villar J. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs. Eur J Ophthalmol. 2014;24:771-777.  https://doi.org/10.5301/ejo.5000455
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.